Crinetics Pharmaceuticals (NASDAQ:CRNX) executives highlighted early commercial momentum for PALSONIFY, outlined a global phase II/III study plan for atumelnant in ACTH-dependent Cushing’s syndrome ...
Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December ...
Your Horse on MSN
Everything you need to know about Cushing’s disease in horses
Equine Cushing’s disease is one of the most common disease syndromes to affect horse health, according to the National Equine Health Survey in 2018*. It is estimated that 20% of horses and ponies over ...
Touro University researchers have found that particles in the blood shuttle hormones through the body, including the brain.
RANCHO CUCAMONGA - Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced Monday it has entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for a ...
MORE than 70 patients with cutaneous diseases have been treated at Massachusetts General Hospital, Peter Bent Brigham Hospital, Robert Breck Brigham Hospital and Children's Hospital with ACTH or ...
Adrenal hormone function was restored in animal studies, potentially paving the way for a functional cure for primary adrenal insufficiency in humans, according to research being presented by Aspect ...
Comparison of sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guérin in the treatment of non-muscle invasive bladder cancer: A meta-analysis. A first-in-human trial of ...
A year had passed since the Mayo Clinic first announced the dramatic effects of treating rheumatoid arthritis sufferers with the hormones ACTH and cortisone (TIME, May 2, 1949). In that year, millions ...
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, announced positive topline results from an open-label, phase 2 congenital adrenal hyperplasia (CAH) study of investigational ...
Crinetics Pharmaceuticals announced positive topline results from a Phase 2 study of atumelnant, a novel oral ACTH receptor antagonist, for treating congenital adrenal hyperplasia (CAH). The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results